DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

PEG-Intron (Peginterferon Alfa-2B) - Hospitalization - Suspected Cause - Side Effect Reports

 
 



Index of reports > Hospitalization (735)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to PEG-Intron (Peginterferon Alfa-2B) hospitalization. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 735   Next >>

Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-27

Patient:

Reactions: Interstitial Lung Disease, Oedema, Hepatic Failure

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Bactrim
    Dosage: 1 df, once
    Administration route: Oral
    Indication: Adverse Event
    End date: 2012-06-09

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-03-13
    End date: 2012-04-04

Rebetol
    Dosage: 800 mg, once
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-13
    End date: 2012-04-04

Telavic
    Dosage: 2250 mg, once
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-13
    End date: 2012-04-04

Other drugs received by patient: Urso 250; Lasix; Celestamine TAB; NEO-Minophagen C; Aldactone



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-27

Patient:

Reactions: Renal Impairment, Anaemia, Pancreatitis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-04-27

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-27
    End date: 2012-05-24

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-05-25

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-27
    End date: 2012-05-17

Other drugs received by patient: Antebate; Prednisolone; Dexaltin; Ubiron; Aspara CA; Loxonin; Onealfa; Diovan; Berizym (Lysozyme Chloride); Mirobect; Amlodipine; Isoleucine (+) Leucine (+) Valine; Lansoprazole; Mucosta



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-27

Patient:

Reactions: Drug Eruption, Haemoglobin Decreased, Malaise, Hyperglycaemia, Decreased Appetite

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-05-17

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-17
    End date: 2012-06-13

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-06-14
    End date: 2012-06-28

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-07-18
    End date: 2012-07-26

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-17
    End date: 2012-05-25

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral

Other drugs received by patient: Motilium; Gasmotin; Diflorasone Diacetate; Nizatidine



Possible PEG-Intron side effects in 59 year old female

Reported by a physician from Canada on 2012-08-27

Patient: 59 year old female, weighing 44.0 kg (96.8 pounds)

Reactions: Oesophageal Varices Haemorrhage, Ascites

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Incivek
    Dosage: 750 mg, tid
    Administration route: Oral
    Indication: Hepatitis C

PEG-Intron
    Dosage: 120 unk, unk
    Indication: Hepatitis C

Other drugs received by patient: Nadolol; Lasix; Atenolol; Spironolactone; Eprex



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-27

Patient:

Reactions: Malaise, Renal Impairment, Decreased Appetite

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, unk
    Indication: Hepatitis C
    Start date: 2012-06-06

Rebetol
    Dosage: 600 mg, unk
    Administration route: Oral
    Start date: 2012-06-15
    End date: 2012-06-20

Rebetol
    Dosage: 200 mg, unk
    Administration route: Oral
    Start date: 2012-06-21
    End date: 2012-07-12

Rebetol
    Dosage: 800 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-06
    End date: 2012-06-14

Rebetol
    Dosage: 200 mg, qod
    Administration route: Oral
    Start date: 2012-07-13

Telavic
    Dosage: 1500 mg, unk
    Administration route: Oral
    Start date: 2012-06-08

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-06
    End date: 2012-06-07

Other drugs received by patient: Lendormin; Lansoprazole; Amoban



Possible PEG-Intron side effects in female

Reported by a consumer/non-health professional from United States on 2012-08-27

Patient: female

Reactions: Dehydration, Anaemia, Lower Respiratory Tract Inflammation

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-02-15

Ribavirin
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-02-15

VX-950
    Dosage: 750 mg, tid
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-15



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-27

Patient:

Reactions: Rash

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, unk
    Start date: 2012-06-19

Rebetol
    Dosage: 600 mg, unk
    Administration route: Oral
    Start date: 2012-06-19

Rebetol
    Dosage: 400 mg, unk
    Administration route: Oral
    Start date: 2012-07-03

Telavic
    Dosage: 2250 mg, unk
    Administration route: Oral
    Start date: 2012-06-19



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-27

Patient:

Reactions: Anaemia, Rash, Haemolytic Anaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-31
    End date: 2012-03-16

PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-01-31
    End date: 2012-03-15

Ribavirin
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-04-24
    End date: 2012-05-21

Ribavirin
    Dosage: 500 mg, qd
    Administration route: Oral
    Start date: 2012-05-22

Ribavirin
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-03-21
    End date: 2012-04-03

Ribavirin
    Dosage: 400 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-31
    End date: 2012-02-27

Ribavirin
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-02-28
    End date: 2012-03-17

Ribavirin
    Dosage: 300 mg, qd
    Administration route: Oral
    Start date: 2012-04-04
    End date: 2012-04-23

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-31
    End date: 2012-03-16

Other drugs received by patient: Coniel; Famotidine; Allopurinol; Celestamine (Betamethasone (+) Dexchlorpheniramine Maleate (+) Fluphen; Isosorbide Dinitrate



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-27

Patient:

Reactions: Pancreatitis Acute, Anaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-05-11
    End date: 2012-06-15

Rebetol
    Dosage: 800 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-11
    End date: 2012-06-20

Telaprevir
    Dosage: 2250 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-11
    End date: 2012-06-20

Other drugs received by patient: Talion (Bepotastine Besylate); Feburic; Famostagine D; NEO-Minophagen C; Urdeston; Trebianom; Sitagliptin Phosphate



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-25

Patient:

Reactions: Gastrointestinal Haemorrhage, Anaemia, Haematemesis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2011-11-02
    End date: 2012-06-27

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-02
    End date: 2012-05-28

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-05-29
    End date: 2012-06-30

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Start date: 2012-05-14
    End date: 2012-05-22

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-05-23
    End date: 2012-06-30

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-09
    End date: 2012-05-11



Possible PEG-Intron side effects in

Reported by a pharmacist from Japan on 2012-08-25

Patient:

Reactions: Neutrophil Count Decreased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 0.75 microgram per kilogram, unk
    Start date: 2012-07-16

PEG-Intron
    Dosage: 1.5mcg/kg
    Start date: 2012-07-09

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Start date: 2012-07-09

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Start date: 2012-07-09

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-07-13



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-25

Patient:

Reactions: Pleurisy

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 100 microgram per kilogram, 5 times a week

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-25

Patient:

Reactions: Rash Erythematous

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 mcg/kg
    Indication: Hepatitis C

Rebetol
    Dosage: 1 g, qd
    Administration route: Oral
    Indication: Hepatitis C

Telavic
    Dosage: 2.25 g, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-04

Other drugs received by patient: Rabeprazole Sodium; Talion (Bepotastine Besylate); Amlodipine Besylate; Loxonin



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Renal Impairment, Vomiting, Nausea, Dizziness, General Physical Health Deterioration

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Glycyron
    Dosage: 6 df, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-14
    End date: 2012-07-04

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-04-10
    End date: 2012-04-16

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-10
    End date: 2012-04-12

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Start date: 2012-04-13
    End date: 2012-04-16

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-10
    End date: 2012-04-16

Other drugs received by patient: Adalat CC; Olmesartan Medoxomil; Olmesartan Medoxomil; Loxonin; Loxonin; Adalat CC; Adalat CC; Glycyron; Doxazosin Mesylate; Metformin HCL; Kinedak; Adalat CC; Nesina; Loxonin; Potassium Chloride; Trichlormethiazide; Amaryl; Lendormin; Allopurinol; Trichlormethiazide; Vitamin E; Primperan TAB; Amaryl; Loxonin; Metformin HCL; Kinedak; Rohypnol; Doxazosin Mesylate; Nesina; Urso 250; Vitamin B12; Electrolytes (Unspecified) (+) Sodium Lactate; Lyrica; Lendormin D



Possible PEG-Intron side effects in

Reported by a physician from Argentina on 2012-08-24

Patient:

Reactions: Anaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded Boceprevir
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-13

PEG-Intron
    Dosage: 150 units
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-06

Peginterferon Alfa-2B
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-13

Placebo
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-13

Ribavirin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-13

Ribavirin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-12

Simvastatin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Start date: 2010-07-15
    End date: 2011-01-13

Simvastatin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-13

Simvastatin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Start date: 2010-07-15
    End date: 2011-01-13

Simvastatin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Start date: 2010-07-15
    End date: 2011-01-13

Simvastatin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-07-15
    End date: 2011-01-13

Simvastatin
    Dosage: 2400 mg, unk
    Administration route: Oral
    Start date: 2010-07-15
    End date: 2011-01-13



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Haemoglobin Decreased, Dizziness

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-06-11

Rebetol
    Dosage: unk

Rebetol
    Dosage: 200 mg, unk
    Administration route: Oral
    Start date: 2012-06-25
    End date: 2012-07-16

Rebetol
    Dosage: 400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-11
    End date: 2012-06-24

Telavic
    Dosage: 2250 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-11
    End date: 2012-06-15

Telavic
    Dosage: 1500 mg, unk
    Administration route: Oral
    Start date: 2012-06-16
    End date: 2012-07-02

Telavic
    Dosage: 1000 unk, unk
    Administration route: Oral
    Start date: 2012-07-03
    End date: 2012-07-09

Other drugs received by patient: Valsartan and Hydrochlorothiazide



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Haemoglobin Decreased, Hepatic Function Abnormal, Erythema

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-07
    End date: 2012-04-30

Incivek
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-07
    End date: 2012-04-30

PEG-Intron
    Dosage: 1.2mcg/kg/week
    Start date: 2012-03-23

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-01-13
    End date: 2012-03-22

PEG-Intron
    Dosage: 1.5 microgram per kilogram, unk
    End date: 2012-05-04

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-04-20

Rebetol
    Dosage: 400 mg, once
    Administration route: Oral
    Start date: 2012-04-20
    End date: 2012-05-11

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-13
    End date: 2012-04-19

Other drugs received by patient: Branute; Allegra; Selbex; Loxoprofen; Posterisan; Posterisan; Heparinoid; Flurbiprofen; Branute; Hirudoid; Livostin; Flurbiprofen; Livostin; Allegra



Possible PEG-Intron side effects in

Reported by a physician from United States on 2012-08-24

Patient:

Reactions: Blood Disorder, Underdose

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from Belgium on 2012-08-24

Patient:

Reactions: Weight Decreased, Tongue Disorder, Anaemia, Decreased Appetite

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 150 microgram, qw
    Indication: Hepatitis C
    Start date: 2012-04-24
    End date: 2012-01-01

PEG-Intron
    Dosage: 120 microgram, qw
    Start date: 2012-01-01

Rebetol
    Dosage: 2x 200 mg in the morning and 200 mg in the evening
    Start date: 2012-08-09

Rebetol
    Dosage: unk unk, bid
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-24
    End date: 2012-01-01

Rebetol
    Dosage: 600 mg in the morning and 400 mg in the evening
    Administration route: Oral
    Start date: 2012-01-01
    End date: 2012-08-08

Other drugs received by patient: Vasexten; Januvia; Valsartan and Hydrochlorothiazide; Glucophage; Nobiten



Possible PEG-Intron side effects in 54 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-24

Patient: 54 year old female

Reactions: Anxiety Disorder, Nausea, Insomnia, Decreased Appetite

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Indication: Hepatitis C
    Start date: 2012-02-15

Ribavirin
    Dosage: 400 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-15
    End date: 2012-02-28

Ribavirin
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-02-29
    End date: 2012-06-12

Ribavirin
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-06-13
    End date: 2012-06-19

Ribavirin
    Dosage: 600 mg, qd
    Administration route: Oral
    Start date: 2012-06-20
    End date: 2012-07-31

VX-950
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-15
    End date: 2012-02-21

VX-950
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-02-22
    End date: 2012-05-08

Other drugs received by patient: Ursodiol; Loxonin; Loxonin; Omeprazole; Januvia; Loxonin



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from Japan on 2012-08-24

Patient:

Reactions: Erythema Multiforme

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-04-18
    End date: 2012-05-23

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    End date: 2012-05-30

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-18

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-18
    End date: 2012-05-30

Other drugs received by patient: Enalapril Maleate



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-24

Patient:

Reactions: Rash

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.4 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-05-30
    End date: 2012-07-04

Prednisolone
    Dosage: 50 mg, qd, formulation : por
    Administration route: Oral
    Start date: 2012-07-10

Prednisolone
    Dosage: 20 mg, qd, formulation : por
    Administration route: Oral
    Start date: 2012-07-02

Prednisolone
    Dosage: 10 mg, qd, formulation : por
    Administration route: Oral
    Start date: 2012-07-04

Prednisolone
    Dosage: 20 mg, qd, formulation : por
    Administration route: Oral
    Start date: 2012-07-06

Prednisolone
    Dosage: 60 mg, qd, formulation : por
    Administration route: Oral
    Start date: 2012-07-08

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-30
    End date: 2012-06-12

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-06-13
    End date: 2012-07-07

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-30
    End date: 2012-07-07

Other drugs received by patient: Alendronate Sodium; Acetaminophen; Clobetasol Propionate; Kindavate; Levofloxacin; Allegra; Famotidine; Rabeprazole Sodium; Azunol (Sodium Gualenate)



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Cerebral Haemorrhage

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-06-05

Rebetol
    Dosage: 200 mg, once
    Administration route: Oral
    Start date: 2012-07-03

Rebetol
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-05
    End date: 2012-06-26

Rebetol
    Administration route: Oral
    Start date: 2012-07-03

Rebetol
    Administration route: Oral
    Start date: 2012-06-27
    End date: 2012-07-02

Rebetol
    Administration route: Oral
    Start date: 2012-06-27
    End date: 2012-07-02

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-05

Other drugs received by patient: Claritin; Posterisan; Lobu; Ferrous Citrate



Possible PEG-Intron side effects in

Reported by a physician from United States on 2012-08-24

Patient:

Reactions: Intestinal Polyp, Gastrointestinal Haemorrhage

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Norvasc

PEG-Intron
    Dosage: unk, qw
    Indication: Hepatitis C
    Start date: 2012-02-16

Ribavirin
    Dosage: 600 mg, bid
    Administration route: Oral

Telaprevir
    Dosage: 750 mg, q8h
    Administration route: Oral

Other drugs received by patient: Centrum (Minerals (Unspecified) (+) Vitamins (Unspecified)); Xanthophyll



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Blood Creatinine Increased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-03-07

Antiviral (Unspecified)
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-10
    End date: 2012-03-06

Lorfenamin
    Dosage: unk unk, unknown
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    End date: 2012-02-14

Lorfenamin
    Dosage: 80mg/day, prn
    Administration route: Oral
    Indication: Prophylaxis
    Start date: 2012-02-10
    End date: 2012-02-14

PEG-Intron
    Dosage: 1.5 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-02-10

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Start date: 2012-03-07
    End date: 2012-03-13

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Start date: 2012-03-28
    End date: 2012-04-03

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-03-14
    End date: 2012-03-27

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-10
    End date: 2012-03-06

Rebetol
    Dosage: 500 mg, qd
    Administration route: Oral
    Start date: 2012-04-04

Telavic
    Dosage: 1500 mg, once
    Administration route: Oral
    Start date: 2012-03-07

Telavic
    Dosage: 2250 mg, once
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-02-10
    End date: 2012-03-06

Other drugs received by patient: Acetaminophen; Locoid; Topsym (Fluocinonide); Acetaminophen



Possible PEG-Intron side effects in

Reported by a individual with unspecified qualification from Japan on 2012-08-24

Patient:

Reactions: Pyelonephritis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-13
    End date: 2012-04-24

PEG-Intron
    Dosage: 1.5 ?g/kg, qw
    Indication: Hepatitis C
    End date: 2012-04-24

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Start date: 2012-03-13
    End date: 2012-04-24

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Start date: 2012-05-08

Rebetol
    Dosage: 400 mg, qd
    Administration route: Oral
    Start date: 2012-04-03
    End date: 2012-04-24

Rebetol
    Dosage: 800 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    End date: 2012-04-02

Rebetol
    Administration route: Oral
    Start date: 2012-03-13
    End date: 2012-04-02

Telavic
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-13
    End date: 2012-04-24

Other drugs received by patient: Lasix; Enalapril Maleate; Amlodipine; Amlodipine Besylate; Amlodipine Besylate; Enalapril Maleate; Lactic Acid; Amlodipine Besylate; Enalapril Maleate; Levothyroxine Sodium; Levothyroxine Sodium; Lasix; Rebamipide; Lansoprazole; Flomox; Lacb R; Rebamipide OD; Lansoprazole



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Bone Marrow Failure

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 0.08 unk, unk
    Start date: 2012-06-14
    End date: 2012-06-22

PEG-Intron
    Dosage: 0.83 microgram per kilogram, qw
    Indication: Hepatitis C
    Start date: 2012-04-26
    End date: 2012-05-01

PEG-Intron
    Dosage: 0.21 microgram per kilogram, unk
    Start date: 2012-05-30

PEG-Intron
    Dosage: 0.42 microgram per kilogram, qw
    Start date: 2012-05-02
    End date: 2012-05-30

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-05-17
    End date: 2012-06-28

Rebetol
    Dosage: 400 unk, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-26
    End date: 2012-05-16

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-04-26
    End date: 2012-06-28

Other drugs received by patient: Talion (Bepotastine Besylate); Rabeprazole Sodium; Talion (Bepotastine Besylate); Allopurinol



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from Colombia on 2012-08-24

Patient:

Reactions: Lymphocytosis, Full Blood Count Abnormal, Thrombocytopenia, Bicytopenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 80 microgram, unk
    Indication: Hepatitis C
    Start date: 2012-05-30

Rebetol
    Dosage: 100 mg, unk
    Administration route: Oral

Victrelis
    Dosage: 2400 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-30



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Vomiting

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk unk, unknown
    End date: 2012-04-16

PEG-Intron
    Dosage: 1.5 ?g/kg, qw
    Start date: 2012-03-14
    End date: 2012-04-13

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-04-12
    End date: 2012-04-16

Rebetol
    Dosage: 600 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-14
    End date: 2012-04-11

Telavic
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-04-14
    End date: 2012-04-16

Telavic
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-14
    End date: 2012-04-12

Telavic
    Dosage: 1750 mg, qd
    Administration route: Oral
    Start date: 2012-04-13
    End date: 2012-04-13

Other drugs received by patient: Dextrose (+) Electrolytes (Unspecified) (+) Sodium Lactate; Cyanocobalamin (+) Pyridoxine Hydrochloride (+) Thiamine Disulfide; Urso 250; Amino Acids (Unspecified); Fladd; Amlodipine Besylate; Selbex; Myser (Cycloserine); Ascorbic Acid; Olopatadine HCL; Neomallermin TR; Marzulene ES; Lansoprazole; Ascorbic Acid (+) Vitamin B Complex



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-08-24

Patient:

Reactions: Pancreatitis Acute, Amylase Increased, Anaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Antiviral (Unspecified)
    Dosage: 2250 mg, qd
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-17
    End date: 2012-02-29

Antiviral (Unspecified)
    Dosage: 1500 mg, qd
    Administration route: Oral
    Start date: 2012-03-01
    End date: 2012-03-20

PEG-Intron
    Dosage: 1.5mcg/kg/week
    Indication: Hepatitis C
    Start date: 2012-01-17
    End date: 2012-03-27

Rebetol
    Dosage: 200 mg, qd
    Administration route: Oral
    Start date: 2012-01-31
    End date: 2012-03-20

Rebetol
    Dosage: 600 mg, once
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-17
    End date: 2012-01-30

Telavic
    Dosage: 2250 mg, once
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-17
    End date: 2012-02-29

Telavic
    Dosage: 1500 mg, once
    Administration route: Oral
    Start date: 2012-03-01
    End date: 2012-03-20

Telavic
    Dosage: unk

Other drugs received by patient: Glufast; Glufast; Tamiflu; Zantac; Primperan TAB; Tamiflu; Acetaminophen; Zantac



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014